Author(s)

Reika Aoyama¹, Atsushi Tanemura^1*, Madoka Takafuji¹, Yorihisa Kotobuki¹, Aya Tanaka¹, Ichiro Katayama¹, Satoshi Takenaka²

¹Department of Dermatology, Graduate School of Medicine, Osaka University, Osaka, Japan.
²Department of Orthopedics, Graduate School of Medicine, Osaka University, Osaka, Japan.

Trabectedin is a synthetic antineoplastic drug, binding to the minor groove of DNA and affecting DNA repair pathways, resulting in G2-M cell cycle arrest and apoptosis. Trabectedin has demonstrated high efficacy against various soft tissue sarcomas. However, its extravasation causes serious complications, such as tissue necrosis and a delay in the treatment of underlying diseases. Methods: We experienced a rare case in which trabectedin extravasation caused severe pectoralis major muscle necrosis. A 45-year-old man with multiple lung metastases of follicular dendritic cell sarcoma received 2.15 mg of trabectedin totally through a central venous access device (CVAD) system in the right precordium. Computed tomography showed extensive turbidity of subcutaneous fatty tissue and swelling of the pectoralis major muscle to the upper margin of the liver, and the creatine kinase level was elevated to 759 U/L (reference value from 54 to 286). We performed surgical debridement twice, and the CVAD was concomitantly removed; thereafter, the skin defect was reconstructed with a split skin mesh graft. Results: Histopathology showed extreme degeneration of striated muscle and fatty tissue. Unfortunately, disability of the right arm abducens persisted after treatment because of debridement around the right humerus muscle. Discussion: Several reports have described cases of the extravasation of trabectedin. A few have mentioned severe muscular degeneration similar to that shown in the present case. Because trabectedin is a strong vesicant cytotoxic agent, it is principally administered through a CVAD rather than peripheral vessels and is continued during the nighttime; this can lead to a delay in patients or attending doctors noticing any extravasation. We need to spread appropriate knowledge of this drug and make an effort to prevent severe complications like in the present case.

Trabectedin, Management of Extravasation, Vesicant Drug, Follicular Dendritic Cell Sarcoma, Muscular Involvement

Aoyama, R. , Tanemura, A. , Takafuji, M. , Kotobuki, Y. , Tanaka, A. , Katayama, I. and Takenaka, S. (2018) A Rare Case of Severe Muscular Necrosis Due to Extravascular Leakage of Trabectedin—Severe Tissue Damage of Trabectedin Extravasation. Journal of Cosmetics, Dermatological Sciences and Applications, 8, 6-9. doi: 10.4236/jcdsa.2018.81002.